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Abstract
Chronic Obstructive Pulmonary Disease (COPD) is and will remain a major cause of morbidity and
mortality worldwide. The severity of airflow obstruction is known to relate to overall health status
and mortality. However, even allowing for common aetiological factors, a link has been identified
between COPD and other systemic diseases such as cardiovascular disease, diabetes and
osteoporosis.
COPD is known to be an inflammatory condition and neutrophil elastase has long been considered
a significant mediator of the disease. Pro-inflammatory cytokines, in particular TNF-α (Tumour
Necrosis Factor alpha), may be the driving force behind the disease process. However, the roles
of inflammation and these pro-inflammatory cytokines may extend beyond the lungs and play a part
in the systemic effects of the disease and associated co-morbidities. This article describes the
mechanisms involved and proposes a common inflammatory TNF-α phenotype that may, in part,
account for the associations.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is and
will remain a major cause of morbidity and mortality
Worldwide [1]. The severity of the airflow obstruction as
assessed by the forced expired volume in 1 second (FEV1)
is a predictor of overall health status [2] and mortality
from both respiratory disease [3] and all causes [4].
Recently interest has arisen because of the association of
COPD with other systemic diseases including cardiovas-
cular disease [5], diabetes [6], osteoporosis [7] and peptic
ulceration [8]. Whereas these associations may represent
common aetiological factors such as cigarette smoking
and steroid usage, careful studies allowing for these fac-
tors have still identified an unexplained link.
COPD is an inflammatory condition and by-products of
the inflammatory process lead to the tissue damage and
physiological adaptations that typify the condition. The
association with smoking is well known although only a
proportion of smokers (typically attributed to about 15%)
develop clinically important airflow obstruction suggest-
ing a genetic predisposition. In this respect elastase
released from activated neutrophils has long been consid-
ered to be a significant mediator of the disease [9]. Recent
extensive studies involving the smoking mouse model
have confirmed this to be a major mechanism possibly
driven by pro-inflammatory cytokines of which tumour
necrosis factor-alpha (TNF-α) appears to be central [10].
However, the roles of inflammation and these pro-inflam-
matory cytokines have been proposed to extend beyond
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the lung in COPD. In particular, they are thought to play
a key role in the muscle wasting related to severe emphy-
sema and possibly other co-morbidities. This article
describes the mechanisms involved and proposes a com-
mon TNF-α driven physiological process that may, in part,
account for the associations.
COPD and systemic inflammation
Initially, it was thought that the establishment of lung
inflammation resulted in an "overspill" into the circula-
tion producing a low-grade systemic inflammation. How-
ever, soluble tumour necrosis factor receptor (sTNF-R) or
Interleukin-8 (IL-8) in sputum and plasma do not corre-
late [11] suggesting that a simple overspill explanation is
not correct.
Patients with COPD have higher baseline levels of several
circulating inflammatory markers [12]. The reasons are
not clear and it remains unknown whether the systemic
inflammation is a primary or secondary phenomenon.
Specific subsets of patients with COPD have been identi-
fied and those with increased resting energy expenditure
and decreased fat-fee mass have more marked elevation of
stable state C reactive protein (CRP) and lipopolysaccha-
ride binding protein [13]. Furthermore, those with higher
levels of systemic inflammation lack a response to nutri-
tional supplementation [14], raising the possibility that
this may be an associated phenomenon rather than cause
and effect.
Both COPD and smoking have been shown to have nega-
tive effects on markers of oxidative stress. Smoking and
acute exacerbations of COPD resulted in a marked imbal-
ance in redox status [15]. Raised levels of lipid peroxida-
tion products confirm the persistence of increased
oxidative stress and other markers have also been elevated
[16]. The increase in oxidative stress may result in the
inactivation of antiproteases, airspace epithelial damage,
mucus hypersecretion, increased influx of neutrophils
into lung tissue and the expression of pro-inflammatory
mediators [17,18].
Changes have also been noted in various inflammatory
cells in peripheral blood, including neutrophils and lym-
phocytes [19]. Patients with COPD have increased num-
bers of neutrophils in the lungs, increased activation of
neutrophils in peripheral blood and an increase in TNF-α
and sTNF-R. It has been suggested that this indicates the
importance of a TNF-α/neutrophil axis in maintaining the
COPD phenotype [20,21].
The central role of TNF-α in lung inflammation is not
only supported by animal models [10] but has also been
implicated in the COPD phenotype with low body mass
index [7]. Cytokine production by macrophages is
enhanced by hypoxia in vitro [22] and thus the inverse
correlation between arterial oxygen tension and circulat-
ing TNF-α and sTNF-R may be the result of systemic
hypoxia [22]. It is tempting therefore to assume that TNF
inhibition would be as beneficial in COPD as it has been
in other inflammatory conditions such as rheumatoid
arthritis and Crohn's disease [23,24]. However, this was
also hypothesised for congestive heart failure (CHF). TNF-
α is believed to play a key role in the pathogenesis of CHF
and raised levels are associated with a higher mortality in
CHF [25]. However, studies using TNF-α blockade have
shown no benefit and possibly an increase in mortality for
reasons that are not clear [26], suggesting it is not just a
simple cause and effect.
Muscle wasting
Low body mass index (BMI), age, and low arterial oxygen
tension have been shown to be significant independent
predictors of mortality in COPD [27,28]. More specifi-
cally, loss of fat-free mass (FFM) adversely affects respira-
tory and peripheral muscle function, exercise capacity and
health status. Both weight loss and loss of FFM appear to
be the result of a negative energy balance, and are seen
more commonly in emphysema [29].
In starvation and nutritional imbalance there is an adap-
tive reduction in resting energy requirements [30]. In con-
trast (as in cachexia) increased resting energy expenditure
has been noted in many COPD patients, linked to sys-
temic inflammation [13,31]. Furthermore nutritional
intake is also generally adequate (apart from during acute
exacerbations). The traditional view that this increased
basal metabolic rate is due to an increased oxygen con-
sumption by respiratory muscles has been shown to be
only part of the reason [32]. Whilst there is no universally
agreed definition of cachexia (derived from the Greek
kakos [bad] and hexis [condition]), accelerated loss of skel-
etal muscle in the context of a chronic inflammatory
response is a characteristic feature [33], and not limited to
COPD. Patients with cachexia display preferential loss of
FFM, enhanced protein degradation [34] and poor
responsiveness to nutritional interventions [35,36]. In
addition, cachectic patients exhibit changes in the metab-
olism of proteins, lipids and carbohydrates that are
thought to be related to systemic rather than local inflam-
mation [36,37]. Thus muscle wasting in COPD displays
similarities to the cachexia seen in chronic heart failure,
renal failure, acquired immunodeficiency syndrome and
cancer (amongst others). The importance of cachexia in
these conditions is not only that it is associated with
reduced survival [35,38-40], but also that it is related to
poor functional status and health-related quality of life
[33]. Common findings in all these conditions include
increased levels of circulating pro-inflammatory mole-
cules including TNF-α, IL-1, IL-6, IL-8, interferon-γ (INF-Respiratory Research 2006, 7:70 http://respiratory-research.com/content/7/1/70
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γ) and reduced levels of anabolic hormones including
insulin-like growth factors and testosterone [33].
TNF-α plays a central role in the muscle wasting and
weight loss seen in COPD. It has several direct effects
(anorexia, altered levels of circulating hormones and cat-
abolic cytokines, and altered end organ sensitivities to
them) which could promote muscle wasting [41] pre-
dominantly via the ubiquitin pathway. This process is
mediated by nuclear factor-κB (NF-κB), a transcription
factor that is inactive when bound to its inhibitor but
which can be activated by inflammatory cytokines includ-
ing TNF-α [42]. In muscle cells NF-κB can interfere with
skeletal muscle differentiation and repair via inhibition of
MyoD expression [43](Figure 1).
Oudijk et al [20] proposed three different mechanisms by
which TNF-α could induce muscle loss. Firstly, protein
loss can be directly stimulated in the skeletal muscle cells.
Secondly, apoptosis can be stimulated through various
signalling pathways via interaction with the TNF-α recep-
tors on the muscle cells. Thirdly, reactive oxygen species
(ROS) can lead to changes in TNF-α/NF-κB signalling,
although the implications of such changes in this pathway
have yet to be clarified. Nevertheless, it appears that
inflammation and ROS have a synergistic action on mus-
cle breakdown [37] and since COPD is associated with
increased oxidant stress [44] it is likely that this factor also
plays a role.
Diabetes
A common process may explain why patients with COPD
have a 1.8 RR of developing type II diabetes [45]. Epide-
miological studies have provided evidence that indicators
of inflammation can predict the development of diabetes
and glucose disorders [6,46]. Indeed, in the ARIC study
fibrinogen, circulating white blood cells count and lower
serum albumin predicted the development of type II dia-
betes [6]. Furthermore patients with non insulin depend-
ant diabetes mellitus have increased circulating levels of
TNF-α, IL-6 and CRP [47]. For these reasons the roles of
circulating cytokines in the pathogenesis of diabetes and
insulin resistance have received increasing interest. Adi-
pose tissue secretes numerous adipokines which markedly
influence lipid and glucose/insulin metabolism. These
include TNF-α and an antagonist, the "protective", adi-
pose tissue specific, adiponectin.
Sonnenberg and colleagues [48] proposed that TNF-α
might be a mediator of the diabetic process. As described
above, this cytokine acts via its receptor to activate the
nuclear transcription factor NF-κB leading to cytokine
production, up regulation of adhesion molecules and
increasing oxidative stress. Indeed, this latter effect
together with TNF-α may provide a stimulating pathway
that interferes with glucose metabolism and insulin sensi-
tivity. This pathway can be antagonised by adiponectin
which reduces NF-κB activation [49].
This concept is supported by several clinical and experi-
mental observations. Firstly, it is known that TNF-α
expression is increased in patients with weight gain and
Pathogenic process implicated in muscle wasting in COPD Figure 1
Pathogenic process implicated in muscle wasting in COPD. 
Circulating TNF-α present in some patients with COPD 
binds to peripheral muscle cell receptors stimulating the pro-
duction of ROS and apoptosis. In addition the receptor bind-
ing stimulates NF-κB activation, possibly enhanced by ROS. 
Protein loss is caused directly via increased ubiquitin activity, 
and indirectly via decreased MyoD expression decreasing 
myofibril synthesis. Protein loss is amplified by a reduction in 
muscle use. This is the result of a reduction in IGF-1 produc-
tion (leading to a decrease in myofibril synthesis), and an 
increase in ubiquitin activity. TNF-α – tumour necrosis factor 
alpha TNFR – tumour necrosis factor receptor ROS – reac-
tive oxygen species NF-κB – nuclear factor kappa beta Ubq – 
ubiquitin IGF – insulin-like growth factor
Circulating TNF-α
TNF-R binding
↑ROS from
mitochondria
NF-κB activation
↑Ubq/proteasome activity
PROTEIN LOSS
↓Muscle use; 
other local factors
↓IGF-1
↓MYOFIBRIL 
SYNTHESIS
↓MyoD gene expression
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insulin resistance [50]. Perhaps this represents a modulat-
ing effect as TNF-α stimulates lipolysis [51] but TNF-α lev-
els are associated with hyper insulinaemia and insulin
resistance [52]. Other studies have also confirmed that an
acute phase response (CRP) is increased in obesity and
associated with insulin resistance [53]. Furthermore, adi-
ponectin levels are reduced in obesity and associated with
insulin resistance and hyper insulinaemia [54]. However,
the most direct supporting data for this putative axis
comes from the obese, insulin resistant mouse where
TNF-α inhibition improves insulin sensitivity [50].
These observations support the concept that inflamma-
tion as reflected in acute phase proteins are in some way
intimately associated with the development of glucose
intolerance and insulin resistance. This concept is summa-
rized in figure 2 which is derived from the proposal of
Sonnenberg et al [48].
Whereas these studies still raise the issue of cause and
effect there have been attempts at proof of concept. Thia-
zolidinediones are agonists for peroxisome proliferator-
activated receptor gamma (PPARγ) – a ligand-activated
transcription factor belonging to the nuclear hormone
receptor superfamily. This class of drug not only decreases
inflammatory markers including TNF-α, soluble ICAM-1,
fibrinogen, MIP1 and CRP but also improves insulin
action [55-58]. These studies are thus in keeping with a
common inflammatory process/pathway linking COPD
and type II diabetes. They are also consistent with the pre-
dictive role of acute phase proteins in the development of
type II diabetes [6].
Fernandez-Real [59] expanded on this process to relate
the inflammatory mechanism of insulin resistance to
atherosclerosis where similar hypotheses have been pro-
posed.
Atherosclerosis
Ridker et al [60] recently published data indicating that
baseline CRP showed a concentration dependant relative
risk for future cardiovascular events. Pai et al [61] assessed
the risk of coronary heart disease and related this to the
circulating levels of several inflammatory markers. The
authors found that high levels of CRP and IL-6 were sig-
nificantly related to an increased risk in both males and
females. The relative risk was 1.79 for individuals whose
baseline was greater than 3 mg/L.
C-reactive protein is a type I acute phase protein with
properties suggesting it is an archaic form of immunity
which possesses the ability to bind to bacteria subse-
quently facilitating the binding of complement necessary
for bacterial killing and/or phagocytosis. The protein can
increase up to 1000 fold within days of the commence-
The roles of TNF-α, adiponectin and NF-κB in the metabolic  syndrome Figure 2
The roles of TNF-α, adiponectin and NF-κB in the metabolic 
syndrome. [Adapted from Sonnenberg et al (41)] TNF-α 
secreted from adipose tissue in conjunction with circulating 
glucose, FFA and insulin stimulate NF-κB activation. This 
action is opposed by adiponectin (indicated by the broken 
line), also secreted from adipose tissue. Activation of the 
PPARγ pathway (for example by TZDs) has been shown to 
directly increase expression of adiponectin and reduce TNF-
α. Further activation of NF-κB is induced through the result-
ing increase in inflammatory cytokines, adhesion molecules 
and oxidative stress, leading to the clinical manifestations of 
the metabolic syndrome. The metabolic syndrome is a con-
stellation of cardiovascular risk factors that is associated with 
a trebling of risk of type 2 diabetes and a doubling of risk of 
cardiovascular disease. Several definitions have been pro-
posed [80-83] leading to some confusion and differences in 
prevalence rates. The International Diabetes Federation have 
recently proposed a practical, globally applicable definition of 
the syndrome using waist circumference plus any two of 
raised triglycerides, reduced HDL-cholesterol, raised blood 
pressure and raised fasting plasma glucose [84]. TNF-α – 
tumour necrosis factor alpha NF-κB – nuclear factor kappa 
beta FFA – free fatty acid LDL – low-density lipoprotein 
PPARγ – peroxisome proliferator activated receptor gamma 
TZD – thiazolidenedione
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ment of an inflammatory process. TNF-α, IL-1 and IL-6
stimulate CRP synthesis by inducing hepatic gene expres-
sion [62], implicating TNF-α at the core of the process.
CRP is known to bind and cause lattice formation and
precipitation leading to passive haemaglutination. Macro-
phages have receptors for CRP and CRP can increase
cytokine production [63,64]. These features may be cen-
tral to atheroma production. C-reactive protein may
deposit directly on to the arterial wall during atherogene-
sis, possibly via the Fcgamma (Fcγ) receptor [65] facilitat-
ing monocyte adherence through the production of the
monocyte chemokine MCP-1. Further activation can
result in production of other pro-inflammatory cytokines
and differentiation of the monocytes into macrophages
(Figure 3).
In the presence of oxidised low density lipoproteins, CRP
can facilitate the production of foam cells which are the
building blocks of atherosclerotic plaques (figure 3).
Recent studies by Smeeth et al [66] have indicated that the
risk of having a myocardial infarct or cerebrovascular
event are increased greatly within the first 3 days after an
"acute systemic respiratory tract infection", defined by the
authors as pneumonia, acute bronchitis, "chest infec-
tions" or influenza (4.95 RR for myocardial infarct and
3.19 RR for stroke). These events are accompanied by a
well recognised acute inflammatory response and
cytokine production. Indeed in patients with COPD not
only is the baseline CRP over 3 mg/L in almost half of the
patients but the further rise during an acute exacerbation
[67] is also associated with a rise in fibrinogen [68]
increasing the pro thrombotic risk. This may well account
for the increased risk of vascular events in COPD and par-
ticularly the likelihood of the increased mortality within a
few month of hospital admission for an acute exacerba-
tion [69].
Osteoporosis
The risk of osteoporosis with steroid use is well known,
but patients with COPD have an increased risk even in the
absence of steroid use. McEvoy and colleagues [70]
observed that vertebral fractures were present in up to
50% steroid naive males with COPD. More recently stud-
ies by Bolton et al confirmed that osteopoenia was a fea-
ture of COPD and associated with an increase in
circulating TNF-α [7]. Again, the association suggests a
cause and effect.
Post menopausal osteoporosis is related to high serum
levels of TNF-α and IL-6 [71]. It is known that macro-
phages can differentiate into osteoclasts in the presence of
marrow mesenchymal cells. These latter cells release the
cytokine RANK ligand (RANKL) which is a member of the
TNF-α superfamily. TNF-α and IL-1 enhance this process
and can induce RANKL expression in marrow stromal
cells and synergise with RANKL in osteoclastogenesis [72],
although osteoclast formation can also be induced by IL-
6, independent of RANKL [73]. However, other inflam-
matory conditions such as rheumatoid arthritis [74] and
periodontal disease [75] have T cells induced to produce
RANKL and it is therefore likely that a similar process
occurs in COPD.
The role of pro-inflammatory cytokines may therefore be
central to the osteoporosis associated with inflammatory
disease. In support of this concept is the study reported by
Gianni et al [71] who confirmed that Raloxifene was able
to decrease TNF-α transcription and serum levels whilst
increasing bone density. Again these data support a close
The inflammatory processes involved in atherosclerotic  plaque formation Figure 3
The inflammatory processes involved in atherosclerotic 
plaque formation. CRP binds to endothelial cells via the Fcγ 
receptor and is internalized, facilitating monocyte binding via 
the production of MCP-1. Further activation leads to further 
cytokine release and differentiation of the monocytes into 
macrophages. In the presence of oxidized LDL, CRP aids the 
production of foam cells – the basis of an atherosclerotic 
plaque. CRP – C reactive protein TNF-α – tumour necrosis 
factor alpha IL-6 – interleukin-6 MCP1 – monocyte chemo-
tactic protein 1 LDL – low density lipoprotein ROS – reac-
tive oxygen species
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association between the pro-inflammatory processes and
osteopoenia.
Peptic ulceration
Finally peptic ulceration is known to be more frequent in
patients with chronic bronchitis and emphysema [76].
Furthermore, studies in patients with gastric ulcers have
found a decrease in FEV1 and vital capacity in smokers and
non-smokers [8]. More recently Roussos and colleagues
[77] demonstrated that helicobacter sero-positivity is
increased in COPD patients to 77.8% (compared to 54%
in control subjects). Furthermore they noted that sero-
positivity to the greater pro-inflammatory phenotype
expressing CaGA was present in 53.9% of patients com-
pared to 29.3% of controls. Once more, although these
associations could represent common factors such as
smoking and socio-economic status, the authors hypoth-
esised that the chronic activation of inflammatory media-
tors induced by H pylori could amplify the development
of COPD. The increased prevalence of the CaGA positive
strain supports this hypothesis as it can stimulate the
release of IL-1 and TNF-α [78] that may enhance the
endothelial adhesion and migration of inflammatory cells
into the lung. Whether such a process enhances the
inflammatory response to cigarette smoke in the lungs
remains unknown. An alternative suggested by the
authors is that overspill inhalation of H pylori or its exo-
toxins into the lungs may in their own right lead to
chronic airway inflammation and hence tissue damage.
There is, however, no direct evidence of this in COPD,
although the hypothesis is feasible and testable by using
eradication therapy and observing the subsequent decline
in lung function in COPD.
Conclusion
In summary several disease entities occur more com-
monly in the presence of each other and are associated
with similar inflammatory pathophysiology suggesting
that a common process results in the clinical overlap.
TNF-α appears to be a central mediator in this process sug-
gesting that factors influencing its production may lead to
a cascade of events, making several conditions more likely
(Figure 4). COPD may enhance this phenomenon by the
associated release of ROS. Alternatively it is possible that
the systemic inflammatory response to COPD precipitates
disease processes at distant sites in its own right, although
this seems less likely. Whatever the relationship, it does
suggest that COPD patients may present to other special-
ties because of the co-morbidity. Furthermore, the diagno-
sis may be missed because of common symptomatology
(dyspnoea as a result of cardiovascular disease or obesity).
As effective anti-inflammatory therapy becomes available
for COPD it will be of importance not only to monitor the
effect on the lungs but also any associated co-morbidities.
This may explain why inhaled corticosteroids in COPD
are associated with decreased cardiovascular mortality
[79] but clearly further studies are warranted to dissect
this process in detail.
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The central role of TNF-α in co-morbidity associated with  COPD Figure 4
The central role of TNF-α in co-morbidity associated with 
COPD. TNF-α appears to play a central role in the patho-
genesis of COPD and other conditions that are increasingly 
being recognised as systemic inflammatory diseases. Certain 
TNF-α receptor polymorphisms are associated with 
increased severity of disease [85,86] and this may be due to 
enhanced TNF-α effects. CRP levels can be increased directly 
by TNF-α and other cytokines. Elevated CRP levels appear 
to be particularly crucial in the pathogenesis of cardiovascu-
lar disease. ROS released as a result of COPD may enhance 
the likelihood of developing cardiovascular disease, diabetes 
and osteoporosis. TNF-α – tumour necrosis factor – alpha 
CRP – C reactive protein ROS – reactive oxygen species
TNF-α
↑ production / sensitivity
Type 2 
Diabetes
Osteoporosis
Peptic 
ulceration
COPD 
Cardiovascular 
disease 
Cachexia
  CRP
Fibrinogen
CRP
ROSRespiratory Research 2006, 7:70 http://respiratory-research.com/content/7/1/70
Page 7 of 9
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MJS and RAS co-authored the paper
Acknowledgements
The Antitrypsin Deficiency Assessment and Programme for Treatment 
(ADAPT) project is supported by a non-commercial grant from Talecris 
Biotherapeutics.
Dr Anita Pye for proof reading the manuscript and assisting with the figures.
Miss R Lewis for typing the manuscript.
References
1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global
strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease. NHLBI/WHO Glo-
bal Initiative for Chronic Obstructive Lung Disease (GOLD)
Workshop summary.  Am J Respir Crit Care Med 2001,
163:1256-1276.
2. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, Plaza
V, Prieto L, Anto JM: Chronic obstructive pulmonary disease
stage and health-related quality of life. The Quality of Life of
Chronic Obstructive Pulmonary Disease Study Group.  Ann
Intern Med 1997, 127:1072-1079.
3. Thomason MJ, Strachan DP: Which spirometric indices best pre-
dict subsequent death from chronic obstructive pulmonary
disease?  Thorax  2000, 55:785-788.
4. Stavem K, Aaser E, Sandvik L, Bjornholt JV, Erikssen G, Thaulow E,
Erikssen J: Lung function, smoking and mortality in a 26-year
follow-up of healthy middle-aged males.  Eur Respir J 2005,
25:618-625.
5. Sin DD, Man SF: Chronic obstructive pulmonary disease as a
risk factor for cardiovascular morbidity and mortality.  Proc
Am Thorac Soc 2005, 2:8-11.
6. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offen-
bacher S, Azambuja MI, Tracy RP, Heiss G: Markers of inflamma-
tion and prediction of diabetes mellitus in adults
(Atherosclerosis Risk in Communities study): a cohort study.
Lancet 1999, 353:1649-1652.
7. Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD,
Nixon LS, Evans WD, Griffiths TL, Shale DJ: Associated loss of fat-
free mass and bone mineral density in chronic obstructive
pulmonary disease.  Am J Respir Crit Care Med 2004,
170:1286-1293.
8. Kellow JE, Tao Z, Piper DW: Ventilatory function in chronic
peptic ulcer. A controlled study of ventilatory function in
patients with gastric and duodenal ulcer.  Gastroenterology 1986,
91:590-595.
9. Stockley RA: The neutrophil in acute and chronic lung disease.
In Acute Lung Injury: from inflammation to repair Edited by: Bellingan G,
Laurent G. Amsterdam: IOS Press; 2000:69-84. 
10. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL: Tumor
necrosis factor-alpha drives 70% of cigarette smoke-induced
emphysema in the mouse.  Am J Respir Crit Care Med 2004,
170:492-498.
11. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA,
Dentener MA, Wouters EF: Local and systemic inflammation in
patients with chronic obstructive pulmonary disease: soluble
tumor necrosis factor receptors are increased in sputum.  Am
J Respir Crit Care Med 2002, 166:1218-1224.
12. Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between
chronic obstructive pulmonary disease and systemic inflam-
mation: a systematic review and a meta-analysis.  Thorax 2004,
59:574-580.
13. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA,
Wouters EF: Evidence for a relation between metabolic
derangements and increased levels of inflammatory media-
tors in a subgroup of patients with chronic obstructive pul-
monary disease.  Thorax 1996, 51:819-824.
14. Creutzberg EC, Schols AM, Weling-Scheepers CA, Buurman WA,
Wouters EF: Characterization of nonresponse to high caloric
oral nutritional therapy in depleted patients with chronic
obstructive pulmonary disease.  Am J Respir Crit Care Med 2000,
161:745-752.
15. Rahman I, Morrison D, Donaldson K, MacNee W: Systemic oxida-
tive stress in asthma, COPD, and smokers.  Am J Respir Crit Care
Med  1996, 154:1055-1060.
16. Pratico D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA:
Chronic obstructive pulmonary disease is associated with an
increase in urinary levels of isoprostane F2alpha-III, an index
of oxidant stress.  Am J Respir Crit Care Med 1998, 158:1709-1714.
17. Repine JE, Bast A, Lankhorst I: Oxidative stress in chronic
obstructive pulmonary disease. Oxidative Stress Study
Group.  Am J Respir Crit Care Med 1997, 156:341-357.
18. MacNee W, Rahman I: Is oxidative stress central to the patho-
genesis of chronic obstructive pulmonary disease?  Trends Mol
Med 2001, 7:55-62.
19. Sauleda J, Garcia-Palmer FJ, Gonzalez G, Palou A, Agusti AG: The
activity of cytochrome oxidase is increased in circulating
lymphocytes of patients with chronic obstructive pulmonary
disease, asthma, and chronic arthritis.  Am J Respir Crit Care Med
2000, 161:32-35.
20. Oudijk EJ, Lammers JW, Koenderman L: Systemic inflammation
in chronic obstructive pulmonary disease.  Eur Respir J Suppl
2003, 46:5s-13s.
21. Lewis SA, Pavord ID, Stringer JR, Knox AJ, Weiss ST, Britton JR: The
relation between peripheral blood leukocyte counts and res-
piratory symptoms, atopy, lung function, and airway respon-
siveness in adults.  Chest 2001, 119:105-114.
22. Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H,
Kato S, Tomoike H: The relationship between chronic hypox-
emia and activation of the tumor necrosis factor-alpha sys-
tem in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med  2000, 161:1179-1184.
23. National Institute for Clinical Excellence: Guidance on the use of
etanercept and infliximab for the treatment of rheumatoid
arthritis.  2002 [http://www.nice.org.uk/pdf/RA-PDF.pdf].
24. Akobeng AK, Zachos M: Tumor necrosis factor-alpha antibody
for induction of remission in Crohn's disease.  Cochrane Data-
base Syst Rev 2004:CD003574.
25. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL:
Cytokines and cytokine receptors in advanced heart failure:
an analysis of the cytokine database from the Vesnarinone
trial (VEST).  Circulation 2001, 103:2055-2059.
26. Coletta AP, Clark AL, Banarjee P, Cleland JG: Clinical trials
update: RENEWAL (RENAISSANCE and RECOVER) and
ATTACH.  Eur J Heart Fail 2002, 4:559-561.
27. Schols AM, Slangen J, Volovics L, Wouters EF: Weight loss is a
reversible factor in the prognosis of chronic obstructive pul-
monary disease.  Am J Respir Crit Care Med 1998, 157:1791-1797.
28. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez
RA, Pinto Plata V, Cabral HJ: The Body-Mass Index, Airflow
Obstruction, Dyspnea, and Exercise Capacity Index in
Chronic Obstructive Pulmonary Disease.  N Engl J Med 2004,
350:1005-1012.
29. Engelen MP, Schols AM, Lamers RJ, Wouters EF: Different patterns
of chronic tissue wasting among patients with chronic
obstructive pulmonary disease.  Clin Nutr 1999, 18:275-280.
30. Schols AM: Nutritional and metabolic modulation in chronic
obstructive pulmonary disease management.  Eur Respir J Suppl
2003, 46:81s-86s.
31. Baarends EM, Schols AM, Westerterp KR, Wouters EF: Total daily
energy expenditure relative to resting energy expenditure in
clinically stable patients with COPD.  Thorax 1997, 52:780-785.
32. Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X: Sys-
temic effects of chronic obstructive pulmonary disease.  Eur
Respir J 2003, 21:347-360.
33. Kotler DP: Cachexia.  Ann Intern Med 2000, 133:622-634.
34. Morrison WL, Gibson JN, Scrimgeour C, Rennie MJ: Muscle wast-
ing in emphysema.  Clin Sci (Lond) 1988, 75:415-420.
35. Tisdale MJ: Biology of cachexia.  J Natl Cancer Inst  1997,
89:1763-1773.Respiratory Research 2006, 7:70 http://respiratory-research.com/content/7/1/70
Page 8 of 9
(page number not for citation purposes)
36. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF: Physi-
ologic effects of nutritional support and anabolic steroids in
patients with chronic obstructive pulmonary disease. A pla-
cebo-controlled randomized trial.  Am J Respir Crit Care Med
1995, 152:1268-1274.
37. Debigare R, Cote CH, Maltais F: Peripheral muscle wasting in
chronic obstructive pulmonary disease. Clinical relevance
and mechanisms.  Am J Respir Crit Care Med 2001, 164:1712-1717.
38. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe
KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ: Wasting as
independent risk factor for mortality in chronic heart failure.
Lancet 1997, 349:1050-1053.
39. Kopple JD: Pathophysiology of protein-energy wasting in
chronic renal failure.  J Nutr 1999, 129:247S-251S.
40. Macallan DC: Wasting in HIV infection and AIDS.  J Nutr  1999,
129:238S-242S.
41. Stewart CE, Newcomb PV, Holly JM: Multifaceted roles of TNF-
alpha in myoblast destruction: a multitude of signal trans-
duction pathways.  J Cell Physiol 2004, 198:237-247.
42. Reid MB, Li YP: Tumor necrosis factor-alpha and muscle wast-
ing: a cellular perspective.  Respir Res 2001, 2:269-272.
43. Gordon JN, Green SR, Goggin PM: Cancer cachexia.  Qjm  2005,
98:779-788.
44. Barreiro E, de la Puente B, Minguella J, Corominas JM, Serrano S, Hus-
sain SN, Gea J: Oxidative stress and respiratory muscle dys-
function in severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2005, 171:1116-1124.
45. Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA,
Speizer FE, Barr RG, Camargo CA Jr: Chronic obstructive pulmo-
nary disease, asthma, and risk of type 2 diabetes in women.
Diabetes Care 2004, 27:2478-2484.
46. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick
HE, Tracy RP: The relation of markers of inflammation to the
development of glucose disorders in the elderly: the Cardio-
vascular Health Study.  Diabetes 2001, 50:2384-2389.
47. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease
of the innate immune system: association of acute-phase
reactants and interleukin-6 with metabolic syndrome X.  Dia-
betologia 1997, 40:1286-1292.
48. Sonnenberg GE, Krakower GR, Kissebah AH: A novel pathway to
the manifestations of metabolic syndrome.  Obes Res 2004,
12:180-186.
49. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta
K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T,
Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adi-
pocyte-derived plasma protein, inhibits endothelial NF-kap-
paB signaling through a cAMP-dependent pathway.  Circulation
2000, 102:1296-1301.
50. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman
BM:  IRS-1-mediated inhibition of insulin receptor tyrosine
kinase activity in TNF-alpha- and obesity-induced insulin
resistance.  Science 1996, 271:665-668.
51. Porter MH, Cutchins A, Fine JB, Bai Y, DiGirolamo M: Effects of
TNF-alpha on glucose metabolism and lipolysis in adipose
tissue and isolated fat-cell preparations.  J Lab Clin Med 2002,
139:140-146.
52. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG: Circulating
tumor necrosis factor-alpha concentrations in a native Cana-
dian population with high rates of type 2 diabetes mellitus.  J
Clin Endocrinol Metab 1999, 84:272-278.
53. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H,
Murata C, Otsuka R, Zhu S, Toyoshima H: The metabolic syn-
drome is associated with elevated circulating C-reactive pro-
tein in healthy reference range, a systemic low-grade
inflammatory state.  Int J Obes Relat Metab Disord 2003,
27:443-449.
54. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE,
Tataranni PA: Hypoadiponectinemia in obesity and type 2 dia-
betes: close association with insulin resistance and hyperin-
sulinemia.  J Clin Endocrinol Metab 2001, 86:1930-1935.
55. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E,
Hamouda W, Dandona P: Suppression of nuclear factor-kappaB
and stimulation of inhibitor kappaB by troglitazone: evi-
dence for an anti-inflammatory effect and a potential antia-
therosclerotic effect in the obese.  J Clin Endocrinol Metab 2001,
86:1306-1312.
56. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed
MI: Effect of rosiglitazone treatment on nontraditional mark-
ers of cardiovascular disease in patients with type 2 diabetes
mellitus.  Circulation 2002, 106:679-684.
57. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kita-
moto S, Ichiki T, Takeshita A: Antiinflammatory and antiarteri-
osclerotic effects of pioglitazone.  Hypertension 2002,
40:687-693.
58. Sidhu JS, Cowan D, Kaski JC: The effects of rosiglitazone, a per-
oxisome proliferator-activated receptor-gamma agonist, on
markers of endothelial cell activation, C-reactive protein,
and fibrinogen levels in non-diabetic coronary artery disease
patients.  J Am Coll Cardiol  2003, 42:1757-1763.
59. Fernandez-Real JM, Ricart W: Insulin resistance and chronic car-
diovascular inflammatory syndrome.  Endocr Rev 2003,
24:278-301.
60. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-
reactive protein and low-density lipoprotein cholesterol lev-
els in the prediction of first cardiovascular events.  N Engl J
Med 2002, 347:1557-1565.
61. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan
GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: Inflammatory
markers and the risk of coronary heart disease in men and
women.  N Engl J Med 2004, 351:2599-2610.
62. Albert MA: The role of C-reactive protein in cardiovascular
disease risk.  Curr Cardiol Rep 2000, 2:274-279.
63. Zahedi K, Tebo JM, Siripont J, Klimo GF, Mortensen RF: Binding of
human C-reactive protein to mouse macrophages is medi-
ated by distinct receptors.  J Immunol 1989, 142:2384-2392.
64. Ballou SP, Lozanski G: Induction of inflammatory cytokine
release from cultured human monocytes by C-reactive pro-
tein.  Cytokine 1992, 4:361-368.
65. Devaraj S, Du Clos TW, Jialal I: Binding and internalization of C-
reactive protein by Fcgamma receptors on human aortic
endothelial cells mediates biological effects.  Arterioscler Thromb
Vasc Biol 2005, 25:1359-1363.
66. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P:
Risk of myocardial infarction and stroke after acute infection
or vaccination.  N Engl J Med 2004, 351:2611-2618.
67. Stockley RA, O'Brien C, Pye A, Hill SL: Relationship of sputum
color to nature and outpatient management of acute exac-
erbations of COPD.  Chest 2000, 117:1638-1645.
68. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC,
Bhowmik A, Jeffries DJ, Meade TW: Acute exacerbations of
chronic obstructive pulmonary disease are accompanied by
elevations of plasma fibrinogen and serum IL-6 levels.  Thromb
Haemost 2000, 84:210-215.
69. Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S,
Heredia JL, Garau J: Mortality after hospitalization for COPD.
Chest 2002, 121:1441-1448.
70. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Nie-
woehner DE: Association between corticosteroid use and ver-
tebral fractures in older men with chronic obstructive
pulmonary disease.  Am J Respir Crit Care Med 1998, 157:704-709.
71. Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S,
Patane F, Agliano AM, Spera G, Marigliano V, Ammendola S, Agnusdei
D, Migliaccio S, Scandurra R: Raloxifene modulates interleukin-6
and tumor necrosis factor-alpha synthesis in vivo: results
from a pilot clinical study.  J Clin Endocrinol Metab 2004,
89:6097-6099.
72. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring
J, Pacifici R: Estrogen deficiency induces bone loss by enhanc-
ing T-cell production of TNF-alpha.  J Clin Invest 2000,
106:1229-1237.
73. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA:
Interleukin-6 and interleukin-11 support human osteoclast
formation by a RANKL-independent mechanism.  Bone 2003,
32:1-7.
74. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C,
Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch
ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Pen-
ninger JM: Activated T cells regulate bone loss and joint
destruction in adjuvant arthritis through osteoprotegerin
ligand.  Nature 1999, 402:304-309.
75. Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski RM, Singh B, Ellen
RP, Penninger JM: Functional human T-cell immunity and oste-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2006, 7:70 http://respiratory-research.com/content/7/1/70
Page 9 of 9
(page number not for citation purposes)
oprotegerin ligand control alveolar bone destruction in per-
iodontal infection.  J Clin Invest 2000, 106:R59-67.
76. Arora OP, Kapoor CP, Sobti P: Study of gastroduodenal abnor-
malities in chronic bronchitis and emphysema.  Am J Gastroen-
terol 1968, 50:289-296.
77. Roussos A, Philippou N, Krietsepi V, Anastasakou E, Alepopoulou D,
Koursarakos P, Iliopoulos I, Gourgoulianis K: Helicobacter pylori
seroprevalence in patients with chronic obstructive pulmo-
nary disease.  Respir Med 2005, 99:279-284.
78. Perri F, Clemente R, Festa V, De Ambrosio CC, Quitadamo M, Fusillo
M, Grossi E, Andriulli A: Serum tumour necrosis factor-alpha is
increased in patients with Helicobacter pylori infection and
CagA antibodies.  Ital J Gastroenterol Hepatol 1999, 31:290-294.
79. Sin DD, Man SF: Why are patients with chronic obstructive
pulmonary disease at increased risk of cardiovascular dis-
eases? The potential role of systemic inflammation in
chronic obstructive pulmonary disease.  Circulation 2003,
107:1514-1519.
80. Alberti KG, Zimmet PZ: Definition, diagnosis and classification
of diabetes mellitus and its complications. Part 1: diagnosis
and classification of diabetes mellitus provisional report of a
WHO consultation.  Diabet Med 1998, 15:539-553.
81. Balkau B, Charles MA: Comment on the provisional report
from the WHO consultation. European Group for the Study
of Insulin Resistance (EGIR).  Diabet Med 1999, 16:442-443.
82. Third Report of the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) final report.  Circulation 2002,
106:3143-3421.
83. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman
Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak
SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW: American Col-
lege of Endocrinology position statement on the insulin
resistance syndrome.  Endocr Pract  2003, 9:237-252.
84. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome--a new
worldwide definition.  Lancet 2005, 366:1059-1062.
85. Fernandez-Real JM, Vendrell J, Ricart W, Broch M, Gutierrez C,
Casamitjana R, Oriola J, Richart C: Polymorphism of the tumor
necrosis factor-alpha receptor 2 gene is associated with
obesity, leptin levels, and insulin resistance in young subjects
and diet-treated type 2 diabetic patients.  Diabetes Care 2000,
23:831-837.
86. Sankar VH, Girisha KM, Gilmour A, Singh VP, Sinha N, Tewari S,
Ramesh V, Mastana S, Agrawal S: TNFR2 gene polymorphism in
coronary artery disease.  Indian J Med Sci 2005, 59:104-108.